Hereditary angioedema patients would prefer newer-generation oral prophylaxis

Figures & data

Table 1. Characteristics of survey respondents.

Characteristics	Survey respondents (n = 75)
Age	mean ± SD
Years	39.1 ± 13.1
Gender	n (%)
Male	37 (49.3)
Female	38 (50.7)
Region	n (%)
Northeast	15 (20.0)
Midwest	18 (24.0)
South	28 (37.3)
West	14 (18.7)
Time since HAE diagnosis	mean ± SD
Years	16.7 ± 15.2
HAE type	n (%)
Type I	73 (97.3)
Type II	2 (2.7)
HAE attacks	mean ± SD
Past 3 months	1.2 ± 1.0
Past 6 months	2.6 ± 1.6
	n (%)
Currently treating HAE with at least 1 prescription medication	73 (97.3)
	n (%)
Currently taking medication for HAE prophylaxis^a	48 (64.0)
	n (%)
Have health insurance	72 (96.0)
	Survey respondents with health insurance (n = 72)
Health insurance type^b	n (%)
Private	64 (88.9)
Medicare	7 (9.7)
Medicaid	1 (1.4)
Other	2 (2.8)
Not Sure	1 (1.4)
Have prescription drug coverage	n (%)
	58 (80.6)

Abbreviation. SD: standard deviation.

^aDefined as anyone who uses an HAE medication for prophylaxis regardless of indication for acute or prophylactic treatment.

^bMulti-select response options.

Figure 1. Agreement with statements regarding HAE and prophylactic treatment.

Figure 2. Agreement with statements regarding oral prophylactic HAE medication.

Figure 3. Agreement with statements regarding oral prophylactic HAE medication among patients taking HAE prophylaxis (n = 48).